SWOG 1211: Phase I/II Trial of Elotuzumab + RVd vs RVd Alone in Newly Diagnosed, High-Risk Myeloma

May 29-31, 2020; Online at meetings.asco.org/am
Addition of elotuzumab to RVd induction and maintenance therapy did not improve outcomes in patients with high-risk multiple myeloma
Format: Microsoft PowerPoint (.ppt)
File Size: 216 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Karyopharm Therapeutics

Related Content

Download these expert-selected slides on treatments for early and later-stage relapsed/refractory multiple myeloma

Sagar Lonial, MD Thomas G. Martin, MD Released: October 6, 2022

A focused text activity providing an expert review of the evolution in CLL treatment during the past several years, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 6, 2022 Expired: October 5, 2023

Downloadable slideset on current best practices and standard treatments for the management of CLL/SLL in the first-line and relapsed settings, from Clinical Care Options (CCO).

Farrukh T. Awan, MD Nicole Lamanna, MD Released: October 5, 2022

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff Sharman, MD Released: September 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings